Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCEND: Bevacizumab-800CW for Early Esophageal Cancer Detection
NCT03877601Phase 2Unknown
- Sponsor
- University Medical Center Groningen
- Start
- Jul 2019
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab-IRDye800CW in esophageal cancer, Barrett's esophagus, sponsored by University Medical Center Groningen. Status: unknown.
02
Drugs
bevacizumab-IRDye800CW
03
Conditions
esophageal cancerBarrett's esophagus
Beyond the preview
Go deeper on NCT03877601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03877601.